Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.61 |
| ▸ | CNR1 | P21554 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ULK1 | O75385 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714681 | 0.79 | KDM4E (0.46) | NPC1MAPTRAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3152268 | 0.79 | CNR2 (0.70) | CNR2CNR1MAPT | |
| SCHEMBL3039967 | 0.76 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL13456267 | 0.74 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL13456183 | 0.73 | CNR2 (0.73) | CNR2CNR1 | |
| SCHEMBL3208969 | 0.73 | CNR2 (0.69) | CNR2CNR1 | |
| SCHEMBL3047370 | 0.71 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL3034472 | 0.69 | CNR2 (1.00) | CNR2CNR1KMT2A | |
| SCHEMBL3038915 | 0.69 | CNR2 (0.70) | CNR2CNR1 | |
| SCHEMBL3037152 | 0.69 | CNR2 (1.00) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139852-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | Pharmos Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008075353-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |